tiprankstipranks
Trending News
More News >
Mettler-Toledo International (MTD)
NYSE:MTD

Mettler-Toledo (MTD) AI Stock Analysis

Compare
515 Followers

Top Page

MTD

Mettler-Toledo

(NYSE:MTD)

Select Model
Select Model
Select Model
Neutral 66 (OpenAI - 5.2)
Rating:66Neutral
Price Target:
$1,327.00
▲(13.61% Upside)
Action:ReiteratedDate:02/07/26
The score is primarily supported by strong profitability and free-cash-flow generation plus constructive FY2026 guidance and buybacks. Offsetting this are meaningful balance-sheet risk from high leverage/negative equity, weak current technical momentum, and a premium valuation (P/E ~32.6) that raises execution expectations.
Positive Factors
High Profitability
Mettler-Toledo’s consistently high gross and operating margins reflect pricing power, durable product differentiation, and operational leverage across instruments and services. These margins provide long-term earnings resilience and the ability to fund R&D, service infrastructure, and capital allocation even with modest top-line growth.
Strong Cash Generation
Robust operating cash flow and near‑one‑to‑one free cash flow conversion underpin sustainable internal funding for share repurchases, acquisitions, and capex. Reliable FCF supports long-term financial flexibility and reduces dependence on external financing for strategic investments.
Recurring Service Revenue
A $1B service business and a large serviceable installed base create sticky, recurring revenue and high-margin aftermarket profit. Incremental penetration opportunity and steady service demand in regulated industries enhance revenue visibility and lifecycle monetization over multiple years.
Negative Factors
High Leverage & Negative Equity
Substantial debt combined with negative shareholders’ equity weakens capital structure, raising refinancing and covenant risk during stress periods. High leverage constrains strategic optionality, increases interest sensitivity, and elevates the cost of pursuing M&A or funding large investments.
Tariff-Driven Margin Pressure
Sustained tariffs and trade frictions are structurally compressing gross and operating margins, forcing ongoing mitigation spending and pricing action. Prolonged trade barriers could permanently raise unit costs or limit competitiveness in key geographies, eroding long-term profitability.
Mature Growth & Low Visibility
The company’s modest top-line growth and short backlog make revenues sensitive to cyclical weakness and timing effects in end markets (lab, industrial, food). This reduces revenue predictability, constrains multi-year growth upside, and raises execution risk for ambitious margin or EPS targets.

Mettler-Toledo (MTD) vs. SPDR S&P 500 ETF (SPY)

Mettler-Toledo Business Overview & Revenue Model

Company DescriptionMettler-Toledo International Inc. engages in the manufacture and supply of precision instruments and services worldwide. It operates in five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other. The company's laboratory instruments include laboratory balances, liquid pipetting solutions, automated laboratory reactors, titrators, pH meters, process analytics sensors and analyzer technologies, physical value analyzers, thermal analysis systems, and other analytical instruments; and LabX, a laboratory software platform to manage and analyze data generated from its instruments. Its industrial instruments comprise industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detection, x-ray, checkweighing, camera-based imaging equipment, track-and-trace solutions, and product inspection systems. The company's retail weighing solutions consist of networked scales and software, stand-alone scales, and automated packaging and labeling solutions for handling fresh goods. It serves the life science industry, independent research organizations, and testing labs; food and beverage manufacturers; food retailers; chemical, specialty chemical, and cosmetics companies; food retailers; transportation and logistics, metals, and electronics industries; and the academic community through its direct sales force and indirect distribution channels. The company was incorporated in 1991 and is based in Columbus, Ohio.
How the Company Makes MoneyMettler-Toledo makes money primarily by selling precision instruments and related software into laboratory and industrial end markets, and by earning recurring revenue from services and consumables that support its installed base. Key revenue streams include: (1) Instrument and system sales: one-time sales of laboratory balances and analytical instruments, industrial scales and in-process weighing systems, and product inspection systems (e.g., checkweighers, metal detectors, x-ray inspection). These products are sold directly and through channel partners depending on geography and customer segment. (2) Service revenue: ongoing fees from calibration, preventative maintenance, repairs, qualifications/validation support, and service contracts. This stream is supported by the large installed base of instruments that require periodic verification and uptime support, particularly in regulated or quality-sensitive environments. (3) Consumables and accessories: recurring sales of items such as electrodes and sensors, weigh pans and accessories, printer/labels and other peripherals, and application-specific supplies tied to routine laboratory and production workflows; these purchases repeat over the life of the instrument. (4) Software and automation-related offerings: revenue from instrument software, data connectivity, and automation solutions that integrate weighing and analytical workflows into customer quality and production processes, which can be sold with hardware and supported through updates and services. Important factors contributing to earnings include demand for precision measurement and compliance in regulated industries (e.g., pharmaceuticals and food), the sticky nature of service and consumables attached to installed instruments, and global distribution/service capabilities that enable lifecycle support. Specific details on significant partnerships are null.

Mettler-Toledo Key Performance Indicators (KPIs)

Any
Any
Revenue By Segment
Revenue By Segment
Analyzes income from different business segments, highlighting which areas drive growth and profitability, and where the company might be vulnerable or have expansion opportunities.
Chart InsightsMettler-Toledo's Retail segment experienced a notable surge in 2023, peaking in Q3, but faced a decline by year-end. The Laboratory segment shows steady growth, with a significant uptick expected by the end of 2024, suggesting strong demand resilience. The Industrial segment remains relatively stable, with minor fluctuations, indicating consistent performance. The absence of earnings call insights leaves the reasons for these trends open to market dynamics and internal strategic shifts.
Data provided by:The Fly

Mettler-Toledo Earnings Call Summary

Earnings Call Date:Feb 05, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The call presented a generally positive operational and financial story: the company delivered broad-based sales growth, strong adjusted EPS performance, exceptional free cash flow conversion, clear product and service milestones, and constructive guidance for FY2026 (sales ≈4%, EPS growth 8–9%). Material headwinds remain from tariffs, unfavorable foreign exchange, and margin compression in the recent period, and management is conservatively guiding Q1 given market caution. On balance the positive execution, cash generation, product momentum and maintained/raised guidance outweigh the disclosed challenges.
Q4-2025 Updates
Positive Updates
Quarterly Sales Growth
Q4 sales of $1.1 billion; local-currency sales up 5% (4% excluding previously communicated acquisitions); reported U.S. dollar sales up 8%.
Geographic Strength
Local-currency sales growth by region in Q4: Americas +7% (includes 3% benefit from acquisitions), Europe +4%, Asia/Rest of World +4%, China +3%.
Product Area Outperformance
Q4 growth by product: Product Inspection strong (reported growth 7%; management later noted 11% reported / 7% organic), Food Retail +19%, Industrial +7% (3% acquisition benefit; core Industrial +2% excluding acquisitions), Laboratory +3%, Service +8% (6% organic).
Adjusted EPS and Reported EPS
Q4 adjusted EPS $13.36, up 8% year-over-year; reported EPS $13.98 versus $11.96 prior year. Full-year adjusted EPS increased 4% (8% when excluding 2024 shipping-delay distortions).
Full-Year Guidance and Confidence
FY2026 guidance: local-currency sales growth ~4% (≈3.5% excl. acquisitions); operating margin expected to increase 60–70 bps excluding currency; adjusted EPS guidance $46.05–$46.70 (8%–9% growth).
Free Cash Flow and Balance Sheet Actions
FY2025 adjusted free cash flow $878 million with a conversion ratio of 99% of adjusted net income; FY2026 free cash flow expected ≈$900 million (≈+5% per share); planned share repurchases $825–$875 million.
Service Business Milestone
Service revenues reached $1.0 billion for the first time; Service grew 8% in Q4 (6% organic) and management expects mid–high single-digit growth for the business in 2026; serviceable installed base ≈$3 billion with ~1/3 penetration.
Product and Commercial Innovation
New product launches and go-to-market programs highlighted: Vero electronic pipette (2,800 cycles per charge), X3 Series X-ray inspection solutions, Spinnaker sales & marketing program and automation/digital integration initiatives to drive share gains.
Negative Updates
Gross Margin and Tariff Headwinds
Q4 gross margin 59.8%, down 140 basis points vs. prior year; incremental gross tariff costs were a ~190 basis-point headwind in the quarter and management estimated tariffs reduced operating profit by ~7% in Q4; FY2025 tariffs were a ~$50 million headwind (≈130 bps to operating margin) and reduced EPS growth by ~5%.
Operating Margin Compression
Adjusted operating margin in Q4 was 32.1%, down 160 basis points year-over-year; unfavorable currency was a ~100-basis-point headwind to operating margin in the quarter and ~50 bps for FY2025.
Organic Gross Margin Pressure
Organic gross margin (ex-FX and acquisitions) declined ~20 basis points in Q4 despite ongoing mitigation efforts, reflecting tariff, mix and inventory/FX effects.
Market Caution and Soft End Markets
Management baked in cautious customer behavior for Q1 2026 and assumed gradual improvement through the year; certain end markets remain soft (biotech/academia, some chemical specialty demand) and core Industrial guided to modest growth with Q1 likely flattish.
China and Lab Momentum Moderate
China grew just 3% in Q4 and is guided to low-single-digit growth for 2026; Laboratory had modest Q4 growth (+3%) with some softness in biotech/academic demand and lab products flattish in China.
Mix & Acquisition Effects on Margins
Recent acquisitions (distribution/service oriented) contributed to reported sales growth but produced mix impacts that were dilutive to gross margin; acquired revenue provided 2–3 percentage points of benefit in various line items but complicated margin comparisons.
Visibility and Short Backlog
Management notes limited near-term visibility (seasonality, volatile headlines, Chinese New Year timing); company typically carries only ~1.5 months of backlog, increasing sensitivity to short-term order patterns.
Company Guidance
The company guided 2026 local-currency sales growth of approximately 4% (about 3.5% excl. previously announced acquisitions) with Q1 local-currency sales of ~3%; adjusted EPS for the full year of $46.05–$46.70 (up 8–9%) and Q1 EPS of $8.60–$8.75 (up 5–7%); operating margin expected to be up 60–70 basis points excluding currency (reported margin flat to slightly up), while Q1 margin is expected to be down ~100 bps at the midpoint (flat excl. unfavorable currency); guidance assumes current U.S. import and retaliatory tariffs remain in effect and does not assume a material market improvement versus 2025; FX at recent spot rates is estimated to be about a 1% benefit to full‑year sales (slight EPS headwind) and roughly a 4% benefit to Q1 sales (neutral to EPS); additional financial assumptions include total amortization ≈$78M (purchased intangible amortization ≈$27M pretax, ≈$1.04 excluded from adjusted EPS), interest expense ≈$70M, other income ≈$19M, a pre‑discrete tax rate of ~19%, free cash flow of ≈$900M (≈+5% per share) with Q1 FCF ≈$100M, and share repurchases of $825M–$875M.

Mettler-Toledo Financial Statement Overview

Summary
Strong profitability and cash generation (high margins; ~$849M 2025 free cash flow close to earnings) support a solid fundamental profile, but high debt and negative shareholder equity materially elevate balance-sheet risk and reduce financial flexibility.
Income Statement
84
Very Positive
Profitability is a clear strength: in 2025 revenue was $4.03B with strong gross margin (~57.5%) and healthy operating and net margins (EBIT margin ~27.8%, net margin ~21.6%). Earnings have been resilient and generally improving versus 2023, with net income rising to ~$869M in 2025 from ~$789M in 2023. The main offset is growth: revenue growth was modest in 2024–2025 (roughly low-single-digit after a small decline in 2023), indicating a more mature growth profile.
Balance Sheet
38
Negative
Leverage and capitalization are the key concerns. Total debt is high and fairly steady (~$2.15B in 2025), while shareholders’ equity is negative in 2023–2025 (about -$24M in 2025), which weakens balance-sheet flexibility and makes debt-to-equity and equity-based return metrics distorted/less informative. Total assets increased to ~$3.71B in 2025, but the combination of sizable debt and negative equity increases financial risk even with strong profitability.
Cash Flow
78
Positive
Cash generation is consistently strong. 2025 operating cash flow was ~$956M and free cash flow was ~$849M, with free cash flow running close to net income (about 0.89x in 2025), suggesting earnings quality is solid. The softer spot is momentum: free cash flow declined ~4.6% in 2025 after being roughly flat in 2024, and operating cash flow relative to EBIT is under 1.0 across years (still healthy in absolute dollars, but not a standout conversion vs. operating profit).
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.03B3.87B3.79B3.92B3.72B
Gross Profit2.32B2.25B2.17B2.24B2.11B
EBITDA1.23B1.22B1.18B1.24B1.10B
Net Income869.19M863.14M788.78M872.50M768.99M
Balance Sheet
Total Assets3.71B3.24B3.36B3.49B3.33B
Cash, Cash Equivalents and Short-Term Investments66.89M59.36M69.81M95.97M98.56M
Total Debt2.34B2.13B2.20B2.13B1.80B
Total Liabilities3.74B3.37B3.51B3.47B3.16B
Stockholders Equity-23.64M-126.89M-149.94M24.79M171.42M
Cash Flow
Free Cash Flow848.65M864.45M860.55M737.83M801.25M
Operating Cash Flow955.77M968.35M965.87M859.07M908.83M
Investing Cash Flow-193.87M-119.46M-131.69M-139.40M-314.11M
Financing Cash Flow-755.17M-855.98M-859.59M-716.04M-590.55M

Mettler-Toledo Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1168.00
Price Trends
50DMA
1388.08
Negative
100DMA
1401.90
Negative
200DMA
1320.09
Negative
Market Momentum
MACD
-43.69
Positive
RSI
28.60
Positive
STOCH
22.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTD, the sentiment is Negative. The current price of 1168 is below the 20-day moving average (MA) of 1329.99, below the 50-day MA of 1388.08, and below the 200-day MA of 1320.09, indicating a bearish trend. The MACD of -43.69 indicates Positive momentum. The RSI at 28.60 is Positive, neither overbought nor oversold. The STOCH value of 22.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTD.

Mettler-Toledo Risk Analysis

Mettler-Toledo disclosed 29 risk factors in its most recent earnings report. Mettler-Toledo reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Mettler-Toledo Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Neutral
$22.03B19.4213.88%1.80%13.74%14.87%
69
Neutral
$29.19B35.1728.52%6.90%3.86%
67
Neutral
$137.93B44.806.99%0.53%2.90%-4.81%
66
Neutral
$24.98B33.06-487.21%4.77%7.93%
64
Neutral
$32.62B31.0519.73%0.72%6.73%3.34%
61
Neutral
$184.15B32.3413.15%0.30%3.91%7.09%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MTD
Mettler-Toledo
1,168.00
-33.99
-2.83%
A
Agilent
111.63
-4.76
-4.09%
DHR
Danaher
186.26
-16.56
-8.16%
DGX
Quest Diagnostics
200.88
35.14
21.20%
TMO
Thermo Fisher
475.89
-31.22
-6.16%
WAT
Waters
283.32
-81.12
-22.26%

Mettler-Toledo Corporate Events

Executive/Board Changes
Mettler-Toledo Adds Experienced Independent Director to Board
Positive
Jan 20, 2026

On January 16, 2026, Mettler-Toledo’s board appointed Michael J. Tokich as an independent director, effective February 5, 2026, expanding the board from nine to ten members with compensation aligned to the company’s other independent directors and no related-party arrangements disclosed. Announced publicly on January 20, 2026, the appointment brings to Mettler-Toledo nearly two decades of U.S. public company CFO experience from Tokich’s long tenure at healthcare and life sciences firm STERIS, bolstering the company’s financial, operational and IT expertise at board level and potentially strengthening its governance and strategic oversight for stakeholders.

The most recent analyst rating on (MTD) stock is a Buy with a $1600.00 price target. To see the full list of analyst forecasts on Mettler-Toledo stock, see the MTD Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 07, 2026